Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers
Adoptive Cell Therapies (ACTs) and the infusion of autologous or redirected tumor-specific T-cells have the potential to drastically impact the treatment of a variety of cancers, especially common epithelial cancers. This report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.
- An overview of both the problems and phenomenal opportunities with cell therapy and immunotherapy in general. While there are several biological and also commercial issues still to more completely resolve, perhaps the largest challenges are scalability and compatibility. Most developers begin by creating cell therapies for smaller groups of individuals, and then when they see real promise, the issue of scalability is addressed
- Detailed description about Adoptive Cell Therapy (ACT), how it targets the somatic mutations by infusion of autologous or redirected tumor-specific T-cells and its impact on the treatment of several metastasized malignancies
- A brief examination of the patent landscape
- Insight into the structure and function of T lymphocytes, identification of the different types of T lymphocytes as well as identifying the T Cell growth factor
- Coverage of number of clinical trials being conducted to investigate the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and investigate their use
- Evaluation of methods to improve TIL yield and tumor reactivity e.g. blockage of programmed cell death 1 (PD-1) and the effect of an agonistic 4-1BB antibody on TIL growth
The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.
PAUL TAYLOR is an independent market researcher and analyst focused on the medical industry working on projects for over 20 years for a variety of prestigious clients including Agilent & Philips Medical Systems, Biomatrix, Inc (Genzyme Corporation), GE Medical Systems (Multiple Projects), Amersham Pharmacia Biotech Limited, Amersham Pharmacia Biotech Limited and Baxter Heathcare. He previously worked for multinational medical device and pharmaceutical companies including Bristol-Myers Squibb, Johnson & Johnson and Pfizer on developing and implementing strategic business and marketing plans. His predictive analytics knowledge and models of market research data have been used for biopharmaceutical and biotechnology clients. He has a bachelor's degree and Ph.D. degree in biochemistry from the University of Liverpool and an MBA degree for Oxford Brookes University.